

Targeting tumour microenvironment, a FAKtual challenge in pancreatic cancer

Ezequiel J Tolosa, Martín E Fernández-Zapico 

Acknowledgements We thank Dr Ryan Carr for critically reading the manuscript and providing helpful advice.

Contributors Both authors have equally contributed to the conceptualisation and writing of the manuscript.

Funding This work was supported by National Cancer Institute CA136526.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Check for upd

Published Online First 3 October 2019



► <http://dx.doi.org/10.1136/gutjnl-2018-317424>

Gut 2020;**69**:1–2.

doi:10.1136/gutjnl-2019-318962

ORCID iD

Martín E Fernández-Zapico <http://orcid.org/0000-0002-8089-3907>

REFERENCES

- 1 Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. *Nat Commun* 2015;**6**:8971.
- 2 Erkan M, Adler G, Apte MV, *et al.* StellaTUM: current consensus and discussion on pancreatic stellate cell research. *Gut* 2012;**61**:172–8.
- 3 Erkan M, Reiser-Erkan C, W. Michalski C, *et al.* The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. *Curr Mol Med* 2012;**12**:288–303.
- 4 Hwang RF, Moore T, Arumugam T, *et al.* Cancer-Associated stromal fibroblasts promote pancreatic tumor progression. *Cancer Res* 2008;**68**:918–26.
- 5 Mantoni TS, Lunardi S, Al-Assar O, *et al.* Pancreatic stellate cells radioprotect pancreatic cancer cells through β 1-integrin signaling. *Cancer Res* 2011;**71**:3453–8.
- 6 Olive KP, Jacobetz MA, Davidson CJ, *et al.* Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* 2009;**324**:1457–61.
- 7 Catenacci DVT, Junttila MR, Karrison T, *et al.* Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. *JCO* 2015;**33**:4284–92.
- 8 Özdemir BC, Pentcheva-Hoang T, Carstens JL, *et al.* Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell* 2014;**25**:719–34.
- 9 Rhim AD, Oberstein PE, Thomas DH, *et al.* Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. *Cancer Cell* 2014;**25**:735–47.
- 10 Jiang H, Liu X, Knolhoff BL, *et al.* Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. *Gut* 2020;**69**:122–32.
- 11 Jiang H, Hegde S, Knolhoff BL, *et al.* Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. *Nat Med* 2016;**22**:851–60.